Classify Variant
ACMG/AMP 5-class classification. 28 weighted evidence codes. Auto-suggestion from ClinVar + in-silico consensus (REVEL, CADD, AlphaMissense, SpliceAI, VEST4).
Governed authorities. Every response is sourced from these.ACMG/AMP SF v3.2ClinVargnomADCPICPharmGKB
OMICSCHAT
OmicsChat
Molecular Signout Intelligence. Variants classified. Pharmacogenomics mapped. Trials matched. Every finding evidence-tiered. Free forever.
Every session evidenced · Every row ledgered · Zero PII stored
OmicsChat
Molecular Intelligence
WHAT OMICSCHAT KNOWS
81/81
ACMG SF v3.2
5,000+
precision trials
200K+
GEO series
255/255
MAGIC governance
What You Can Do
MOLECULAR SIGNOUT WORKFLOW
Every service governed. Every finding evidence-tiered. Every interaction ledgered. General genomics education is always free — no sign in required.
Pharmacogenomics
CPIC Level A drug-gene interactions. CYP2D6/tamoxifen, DPYD/5-FU, UGT1A1/irinotecan, TPMT/thiopurines, and more.
GEO Explorer
StarGEO-backed gene expression intelligence. 200K+ NCBI GEO series, 48+ validated disease signatures. NIH BD2K heritage.
Trial Matching
5,000+ precision medicine trials from ClinicalTrials.gov matched by variant and cancer type. mCODE profile-based eligibility.
Actionable Cancer Genes
11 DRIVERS, APPROVED THERAPIES
BRCA1 / BRCA2
Homologous recombination DNA repair. PARP inhibitor eligibility (olaparib, talazoparib). Platinum sensitivity context.
EGFR
Exon 19 deletions + L858R — first-line osimertinib. Resistance mutations (T790M, C797S) tracked with next-line options.
ALK / ROS1 / RET
Fusion drivers in NSCLC. Alectinib, brigatinib, crizotinib, entrectinib, selpercatinib — evidence-mapped by fusion partner.
BRAF V600E
Melanoma, thyroid, colorectal. Dabrafenib + trametinib combination. BRAF+EGFR for CRC (encorafenib + cetuximab).
KRAS G12C
Sotorasib, adagrasib. KRAS G12C-specific inhibitors. NSCLC + CRC approvals. Resistance mechanisms catalogued.
HER2 / NTRK / MSI
HER2 amplification (trastuzumab deruxtecan), NTRK fusions (larotrectinib), MSI-high (pembrolizumab pan-tumor).
Evidence Chain
WHERE OMICSCHAT GETS ITS ANSWERS
ClinVar
NCBI variant classification repository. Star ratings, review status, submitter agreement. ACMG evidence anchor.
PharmGKB
Pharmacogenomics Knowledge Base. CPIC guidelines, drug-gene pairs, clinical annotations.
COSMIC
Catalogue of Somatic Mutations in Cancer. Sanger Institute. Tumor-specific hotspots.
OncoKB
MSK precision oncology knowledge base. Level 1-4 actionability tiers. FDA-approved therapy mapping.
GEO / StarGEO
NCBI Gene Expression Omnibus + StarGEO aggregation. 2M+ samples, 48+ validated disease signatures.
gnomAD
Genome Aggregation Database. Population frequency context — essential for PM2/BA1 criteria.
GTEx
Genotype-Tissue Expression project. Normal tissue expression baselines. Variant-in-context interpretation.
ClinicalTrials.gov
5,000+ precision medicine trials matched by variant, cancer type, and mCODE profile.
Heritage
BUILT ON STARGEO
StarGEO
NIH BD2K UH2CA203792 ($634K). 2M+ GEO samples aggregated into 48+ validated disease signatures. Published in Nature Scientific Data 2017. The foundation OmicsChat is built on.
Multi-Omics Integration
Digital twins + longitudinal multi-omics. Personalized health indices. Blockchain/ledger data security. Validates OmicsChat n-of-1 reasoning architecture.
Access
FREE FOREVER FOR PATIENTS + CLINICIANS
Free
Variant lookup, ACMG classification, pharmacogenomics, trial matching, gene expression queries. No sign in. No credit card. Governed answers with full citation.
Foundation
Enterprise features at zero cost for academic medical centers, precision medicine consortia, and community oncology networks. Request access via the CANONIC Foundation.
Governance
MAGIC 255